Exhibit 99.1

 

FocalTherics™ Reports Third Quarter 2026 Financial Results

 

45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date

 

AUSTIN, Texas, November 5, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”[1]), a global leader in robotic focal therapy, today announced financial results for the third quarter of 2026.

 

Third Quarter 2026 Results and Recent Highlights

 

·Increased Revenue to $9.8 million, a 26% Increase Compared to the Prior Year Period

 

·32% Increase in U.S. Procedure Volume over the Prior Year Period

 

·Recorded Seven Focal One® Capital System Sales compared to Six in the Prior Year Period,

 

·Expanded Focal One System Installed Base to 192, including 98 in the U.S. and 94 Internationally

 

·Increased Gross Margin to 51.4%, Compared to 46.6% in the Prior Year Period

 

·Expanded Commercial Focal One Endometriosis Programs to Three Centers in Europe

 

·Positive Coverage Policies Published by Major Commercial Payers for HIFU in Radiorecurrent Prostate Cancer

 

“We demonstrated steady commercial momentum in the third quarter, highlighted by expanding adoption across multiple new regions and additional system sales in the United States, Turkey, Mexico, and France,” said Ryan Rhodes, CEO of FocalTherics. “U.S. procedure volumes accelerated year-over-year to 32% for the third quarter of 2026, compared to 15% in 2025. Driven by our sustained commercial traction, accelerating technology adoption, and our focus on our HIFU opportunity, we remain highly confident in our growth strategy and on the opportunity ahead as we close out the year.”

 

Third Quarter 2026 Financial Results

 

Total revenue for the third quarter of 2026 was $9.8 million, compared to $7.8 million for the same period in 2025, representing an increase of 26% year-over-year. The Company sold seven Focal One systems during the quarter, versus six systems in the same period in 2025, representing a year-over-year growth of 17%. The Company’s U.S. Focal One procedures grew 32% year-over-year.

 

Gross margin for the third quarter of 2026 was 51.4%, compared to 46.6% in the prior year period. The increase in gross margin was primarily attributable to improvement on standard cost of the Focal One and higher average selling price of our Focal One systems and Focalpaks.

 

Operating expenses were $12.8 million for the third quarter of 2026, compared to $10.3 million in the prior year period. The increase was due to incremental headcount-related compensation costs including higher stock-based compensation, and additional sales and marketing expenses related to various Urology meetings and events.

 

Operating loss was $7.8 million for the third quarter of 2026, compared to $6.7 million in the prior year period. Net loss was $4.5 million for the third quarter of 2026, or ($0.10) per share, compared to a net loss of $5.9 million, or ($0.16) per share in the prior year period. The decrease in net loss was primarily attributable to favorable non-cash impact of $2.6 million related to change in fair value of the European Investment Bank warrants and $0.5 million foreign currency exchange gain, partially offset by the higher operating loss of $1.1 million and $0.4 million of interest expense on the Tranche A and Tranche B drawdown.

 

Cash and cash equivalents as of September 30, 2026 totaled $56.3 million.

 

 

 


Narrowing 2026 Guidance

 

We are narrowing our full-year 2026 revenue guidance to be in the range of $50.0 to $52.0 million, representing 34% to 39% growth over 2025, from the prior range of $50.0 to $54.0 million.

 

We have included standalone historical financials for the HIFU business at the end of the document

 

Conference Call Information

 

A conference call and webcast to discuss the second quarter 2026 financial results will be hosted by Ryan Rhodes, Chief Executive Officer and Ken Mobeck, Chief Financial Officer. Please refer to the information below for conference call dial-in information and webcast registration.

 

Date:  Thursday, November 5, 2026, at 4:30 p.m. Eastern Time
Domestic:  1-833-419-0865
International:  1-785-838-9333
Passcode:  FOCAL 
Webcast:  https://viavid.webcasts.com/starthere.jsp?ei=1776674&tp_key=37ee4700b1

 

About FocalTherics
A recognized global leader in robotic focal therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.

 

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved, and include statements such as quote from our Chief Executive Officer and our narrowed financial performance guidance. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and our ability to successfully discontinue and wind down our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.

 

Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

 

 

 

Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.

 

Investor Contact

Louisa Smith

Gilmartin Group

investor.relations@focalone.com

 

 

 

 

 

 

 

 

 

 

 

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands of U.S. Dollars, except per share data)

 

       
   Three Months Ended:
   September 30,  September 30,
   2026  2025
   $US  $US
Sales of goods   6,489    4,895 
Sales of RPP and leases   2,367    2,216 
Sales of spare parts and services   972    717 
TOTAL NET SALES   9,828    7,828 
Other revenues   —    (0)
TOTAL REVENUES   9,828    7,828 
Cost of sales   (4,776)   (4,181)
GROSS PROFIT   5,053    3,647 
Research & development expenses   (2,458)   (2,303)
Selling, general & administrative expenses   (10,371)   (8,014)
Total operating expenses   (12,829)   (10,316)
LOSS FROM OPERATIONS   (7,777)   (6,669)
Interest (expense) income, net   (559)   (60)
Gain (loss) from change in fair value of warrants liability   2,596    — 
Currency exchange gains (loss), net   467    85 
LOSS BEFORE TAXES FROM CONTINUING OPERATIONS   (5,272)   (6,645)
Income tax (expense) credit, net from continuing operations   (15)   (16)
LOSS FROM CONTINUING OPERATIONS   (5,287)   (6,661)
Income(loss) from discontinued operations, net of tax   825    721 
NET LOSS   (4,462)   (5,940)
Loss per share – Basic and diluted   (0.10)   (0.16)
Average number of shares used in computation of EPS - basic and dilutive   42,625,694    37,438,630 

 

 

 

 

 

 

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands of U.S. Dollars, except per share data)

 

       
   Nine Months Ended:
   September 30,  September 30,
   2026  2025
   $US  $US
Sales of goods   24,272    15,081 
Sales of RPP and leases   7,617    6,315 
Sales of spare parts and services   2,736    2,441 
TOTAL REVENUES   34,624    23,838 
Cost of sales   (16,271)   (12,170)
GROSS PROFIT   18,353    11,667 
Research & development expenses   (7,242)   (6,951)
Selling, general & administrative expenses   (34,945)   (24,753)
Total operating expenses   (42,186)   (31,704)
LOSS FROM OPERATIONS   (23,834)   (20,037)
Interest (expense) income, net   (1,710)   (142)
Gain (loss) from change in fair value of warrants liability   (4,254)   — 
Currency exchange gains (loss), net   544    (579)
LOSS BEFORE TAXES FROM CONTINUING OPERATIONS   (29,254)   (20,757)
Income tax (expense) credit, net from continuing operations   (40)   (39)
LOSS FROM CONTINUING OPERATIONS   (29,294)   (20,796)
Income(loss) from discontinued operations, net of tax   1,263    1,006 
NET LOSS   (28,032)   (19,790)
Loss per share – Basic and diluted   (0.71)   (0.53)
Average number of shares used in computation of EPS - basic and dilutive   39,227,611    37,417,439 

 

 

 

 

 

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands of U.S. Dollars)

 

       
   September 30,  December 31,
   2026  2025
   $US  $US
Cash, cash equivalents and short-term investments   56,269    20,452 
Accounts receivable, net   10,177    14,948 
Inventory   8,329    7,770 
Other current assets   2,681    2,439 
Total current assets of discontinued operations   17,328    11,555 
TOTAL CURRENT ASSETS   94,784    57,164 
Property, plant and equipment, net   9,052    8,789 
Goodwill   732    757 
Other non-current assets   6,149    6,181 
Total non-current assets of discontinued operations   —    6,106 
TOTAL ASSETS   110,717    78,997 
Accounts payable & other accrued liabilities   17,857    17,436 
Deferred revenues, current portion   7,326    6,452 
Short term borrowing   426    4,386 
Other current liabilities   1,318    3,005 
Total current liabilities of discontinued operations   9,143    5,862 
TOTAL CURRENT LIABILITIES   36,070    37,141 
Obligations under operating and finance leases non-current   615    1,183 
Long-term debt, non-current   35,233    15,903 
Deferred revenues, non-current   898    768 
Other long-term liabilities   1,963    1,632 
Total non-current liabilities of discontinued operations   —    2,957 
TOTAL LIABILITIES   74,779    59,584 
TOTAL SHAREHOLDERS’EQUITY   35,938    19,413 
TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY   110,717    78,997 

 

 

 

 

 

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands of U.S. Dollars)

 

       
   Nine Months Ended  Nine Months Ended
   September 30,  September 30,
   2026  2025
   ($US)  ($US)
NET INCOME (LOSS)   (28,032)   (19,790)
Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities(1)   12,450    5,136 
OPERATING CASH FLOW   (15,582)   (14,654)
Increase/Decrease in operating assets and liabilities   4,895    699 
NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES   (10,687)   (13,955)
           
Additions to capitalized assets produced by the company and other capital expenditures   (3,361)   (4,002)
NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES   (3,361)   (4,002)
NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES   50,707    (2,847)
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS   (842)   2,217 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   35,817    (18,587)

 

(1) including share-based compensation expenses for $2,359 thousand for the nine months ended September 30, 2026 and $1,746 thousand for the nine months ended September 30, 2025, as well as warrant fair value adjustment of $3,036 thousand related to Tranche A and $839 thousand related to Tranche B for the nine months ended September 30, 2026

 

 

 

 

 

 

 

 

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

nine months ended September 30, 2026

(Amounts in thousands of U.S. Dollars)

 

                
Nine months ended  HIFU     Reconciling  Total After   
September 30, 2026  Division     Items  Consolidation   
Sales of goods   24,272         —    24,272      
Sales of RPP and leases   7,617         —    7,617      
Sales of spare parts and services   2,736         —    2,736      
TOTAL REVENUES   34,624         —    34,624      
GROSS PROFIT (% of Net Sales)   18,353    53.0%   —    18,353    53.0%
Research & development expenses   (7,242)        —    (7,242)     
Selling, general & administrative expenses   (29,046)        (5,899)   (34,945)     
OPERATING PROFIT (LOSS)   (17,935)        (5,899)   (23,834)     

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

three months ended September 30, 2026

(Amounts in thousands of U.S. Dollars)

 

                
Three months ended  HIFU     Reconciling  Total After   
September 30, 2026  Division     Items  Consolidation   
Sales of goods   6,489         —    6,489      
Sales of RPP and leases   2,367         —    2,367      
Sales of spare parts and services   972         —    972      
TOTAL REVENUES   9,828         (0)   9,828      
GROSS PROFIT (% of Net Sales)   5,053    51.4%   (0)   5,053    51.4%
Research & development expenses   (2,458)        —    (2,458)     
Selling, general & administrative expenses   (8,737)        (1,634)   (10,371)     
OPERATING PROFIT (LOSS)   (6,142)        (1,634)   (7,777)     

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

three months ended June 30, 2026

(Amounts in thousands of U.S. Dollars)

 

                
Three months ended  HIFU     Reconciling  Total After   
June 30, 2026  Division     Items  Consolidation   
Sales of goods   9,527         —    9,527      
Sales of RPP and leases   2,758         —    2,758      
Sales of spare parts and services   918         —    918      
TOTAL REVENUES   13,202         —    13,202      
GROSS PROFIT (% of Net Sales)   7,338    55.6%   —    7,338    55.6%
Research & development expenses   (2,317)        —    (2,317)     
Selling, general & administrative expenses   (10,869)        (2,185)   (13,054)     
OPERATING PROFIT (LOSS)   (5,848)        (2,185)   (8,033)     

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

three months ended March 31, 2026

(Amounts in thousands of U.S. Dollars)

 

                
Three months ended  HIFU     Reconciling  Total After   
March 31, 2026  Division     Items  Consolidation   
Sales of goods   8,256         —    8,256      
Sales of RPP and leases   2,492         —    2,492      
Sales of spare parts and services   845         —    845      
TOTAL REVENUES   11,593         —    11,593      
GROSS PROFIT (% of Net Sales)   5,962    51.4%   —    5,962    51.4%
Research & development expenses   (2,467)        —    (2,467)     
Selling, general & administrative expenses   (9,439)        (2,080)   (11,520)     
OPERATING PROFIT (LOSS)   (5,944)        (2,080)   (8,024)     

 

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

twelve months ended December 31, 2025

(Amounts in thousands of U.S. Dollars)

 

                
Twelve months ended  HIFU     Reconciling  Total After   
December 31, 2025  Division     Items  Consolidation   
Sales of goods   24,857         —    24,857      
Sales of RPP and leases   8,791         —    8,791      
Sales of spare parts and services   3,703         —    3,703      
TOTAL REVENUES   37,351         —    37,351      
GROSS PROFIT (% of Net Sales)   17,978    48.1%   —    17,978    48.1%
Research & development expenses   (8,909)        —    (8,909)     
Selling, general & administrative expenses   (29,748)        (5,843)   (35,591)     
OPERATING PROFIT (LOSS)   (20,679)        (5,843)   (26,522)     

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

three months ended December 31, 2025

(Amounts in thousands of U.S. Dollars)

 

                
Three months ended  HIFU     Reconciling  Total After   
December 31, 2025  Division     Items  Consolidation   
Sales of goods   9,776         —    9,776      
Sales of RPP and leases   2,476         —    2,476      
Sales of spare parts and services   1,262         —    1,262      
TOTAL REVENUES   13,513         (0)   13,513      
GROSS PROFIT (% of Net Sales)   6,311    46.7%   (0)   6,311    46.7%
Research & development expenses   (1,958)        —    (1,958)     
Selling, general & administrative expenses   (8,514)        (2,324)   (10,838)     
OPERATING PROFIT (LOSS)   (4,161)        (2,324)   (6,485)     

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

three months ended September 30, 2025

(Amounts in thousands of U.S. Dollars)

 

                
Three months ended  HIFU     Reconciling  Total After   
September 30, 2025  Division     Items  Consolidation   
Sales of goods   4,895         —    4,895      
Sales of RPP and leases   2,216         —    2,216      
Sales of spare parts and services   717         —    717      
TOTAL REVENUES   7,828         —    7,828      
GROSS PROFIT (% of Net Sales)   3,647    46.6%   —    3,647    46.6%
Research & development expenses   (2,303)        —    (2,303)     
Selling, general & administrative expenses   (6,756)        (1,258)   (8,014)     
OPERATING PROFIT (LOSS)   (5,412)        (1,258)   (6,669)     

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

three months ended June 30, 2025

(Amounts in thousands of U.S. Dollars)

 

                
Three months ended  HIFU     Reconciling  Total After   
June 30, 2025  Division     Items  Consolidation   
Sales of goods   6,385         —    6,385      
Sales of RPP and leases   2,155         —    2,155      
Sales of spare parts and services   969         —    969      
TOTAL REVENUES   9,509         —    9,509      
GROSS PROFIT (% of Net Sales)   4,863    51.1%   —    4,863    51.1%
Research & development expenses   (2,291)        —    (2,291)     
Selling, general & administrative expenses   (8,036)        (1,158)   (9,194)     
OPERATING PROFIT (LOSS)   (5,465)        (1,158)   (6,623)     

 

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

three months ended March 31, 2025

(Amounts in thousands of U.S. Dollars)

 

                
Three months ended  HIFU     Reconciling  Total After   
March 31, 2025  Division     Items  Consolidation   
Sales of goods   3,800         —    3,800      
Sales of RPP and leases   1,945         —    1,945      
Sales of spare parts and services   755         —    755      
TOTAL REVENUES   6,500         —    6,500      
GROSS PROFIT (% of Net Sales)   3,158    48.6%   —    3,158    48.6%
Research & development expenses   (2,358)        —    (2,358)     
Selling, general & administrative expenses   (6,441)        (1,104)   (7,545)     
OPERATING PROFIT (LOSS)   (5,641)        (1,104)   (6,745)     

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

twelve months ended December 31, 2024

(Amounts in thousands of U.S. Dollars)

 

                
Twelve months ended  HIFU     Reconciling  Total After   
December 31, 2024  Division     Items  Consolidation   
Sales of goods   16,046         —    16,046      
Sales of RPP and leases   6,789         —    6,789      
Sales of spare parts and services   2,967         —    2,967      
TOTAL REVENUES   25,803         —    25,803      
GROSS PROFIT (% of Net Sales)   13,283    51.5%   —    13,283    51.5%
Research & development expenses   (7,245)        —    (7,245)     
Selling, general & administrative expenses   (24,936)        (4,585)   (29,520)     
OPERATING PROFIT (LOSS)   (18,897)        (4,585)   (23,482)